Passage Non Recurring from 2010 to 2026

PASG Stock  USD 9.11  1.46  13.81%   
Passage Bio's Non Recurring is increasing over the last several years with slightly volatile swings. Non Recurring is estimated to finish at about 4.4 M this year. During the period from 2010 to 2026 Passage Bio Non Recurring regressed destribution of quarterly values had coefficient of variationof  90.02 and r-value of  0.62. View All Fundamentals
 
Non Recurring  
First Reported
2010-12-31
Previous Quarter
3.5 M
Current Value
4.4 M
Quarterly Volatility
1.9 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Passage Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Passage Bio's main balance sheet or income statement drivers, such as Net Interest Income of 2.7 M, Interest Income of 2.7 M or Depreciation And Amortization of 2.6 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.53. Passage financial statements analysis is a perfect complement when working with Passage Bio Valuation or Volatility modules.
  
Build AI portfolio with Passage Stock
Check out the analysis of Passage Bio Correlation against competitors.
For more detail on how to invest in Passage Stock please use our How to Invest in Passage Bio guide.
The Non Recurring trend for Passage Bio offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Passage Bio is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.

Latest Passage Bio's Non Recurring Growth Pattern

Below is the plot of the Non Recurring of Passage Bio over the last few years. It is Passage Bio's Non Recurring historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Passage Bio's overall financial position and show how it may be relating to other accounts over time.
Non Recurring10 Years Trend
Slightly volatile
   Non Recurring   
       Timeline  

Passage Non Recurring Regression Statistics

Arithmetic Mean2,108,824
Geometric Mean1,609,931
Coefficient Of Variation90.02
Mean Deviation1,434,948
Median1,000,000
Standard Deviation1,898,374
Sample Variance3.6T
Range7M
R-Value0.62
Mean Square Error2.4T
R-Squared0.39
Significance0.01
Slope233,701
Total Sum of Squares57.7T

Passage Non Recurring History

20264.4 M
20253.5 M
2022M
2021M

About Passage Bio Financial Statements

Passage Bio stakeholders use historical fundamental indicators, such as Passage Bio's Non Recurring, to determine how well the company is positioned to perform in the future. Although Passage Bio investors may analyze each financial statement separately, they are all interrelated. For example, changes in Passage Bio's assets and liabilities are reflected in the revenues and expenses on Passage Bio's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Passage Bio. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Non Recurring3.5 M4.4 M

Currently Active Assets on Macroaxis

When determining whether Passage Bio is a strong investment it is important to analyze Passage Bio's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Passage Bio's future performance. For an informed investment choice regarding Passage Stock, refer to the following important reports:
Check out the analysis of Passage Bio Correlation against competitors.
For more detail on how to invest in Passage Stock please use our How to Invest in Passage Bio guide.
You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Can Biotechnology industry sustain growth momentum? Does Passage have expansion opportunities? Factors like these will boost the valuation of Passage Bio. Anticipated expansion of Passage directly elevates investor willingness to pay premium valuations. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Passage Bio demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Earnings Share
(13.58)
Return On Assets
(0.32)
Return On Equity
(0.87)
Investors evaluate Passage Bio using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Passage Bio's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. External factors like market trends, sector rotation, and investor psychology can cause Passage Bio's market price to deviate significantly from intrinsic value.
It's important to distinguish between Passage Bio's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Passage Bio should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Passage Bio's market price signifies the transaction level at which participants voluntarily complete trades.